Close Menu

Hitachi

The Swiss-American bioinformatics company touts its networks of multimodal data and numerous partnerships as it looks to support "data-driven medicine."

The Swiss-American bioinformatics company has now raised more than $250 million and seeks to further expand expand deeper in the US and Asian markets. 

The firms plan to collaborate with others in the field of regenerative medicine and cell therapy to expedite commercialization of the system.

Hitachi and Centre Léon Bérard have opened a research lab in Lyon that will apply AI to medical imaging and predict response to radiation therapy from genomic markers.

The company plans to use the funding to finish developing and commercially launch its HD-Mapping whole-genome electronic mapping platform.

The companies are aiming to develop and establish clinical operation for the assays in Japan, where Hitachi said there is growing demand for such tests.

PSS, which develops tools for the IVD space, will supply to Hitachi its nucleic acid isolation system, fully automated diagnostic instruments, and reagents.

Under the terms of the collaboration, the firms will combine ZS Genetics' proprietary technologies with HTA's experience in high-resolution electron microscopy.

Initial projects include developing new automation systems based on PCR and next-generation sequencing.

Du Pont has been awarded

Pages

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.